<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503773</url>
  </required_header>
  <id_info>
    <org_study_id>CR0014</org_study_id>
    <nct_id>NCT03503773</nct_id>
  </id_info>
  <brief_title>The TARGET BP OFF-MED Trial</brief_title>
  <official_title>A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects With Hypertension, in the Absence of Antihypertensive Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablative Solutions, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablative Solutions, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated
      neurolysis using the Peregrine Kit in hypertensive subjects in the absence of
      antihypertensive medications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects who continue to be eligible at the end of the run-in period will be randomized in a 1:1 ratio to one of the following 2 groups via central randomization (stratified by study site):
Treatment Arm: renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter
Sham Control Arm: only renal angiography performed</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Blinded (The subject, sponsor, and hypertensionist/nephrologist performing the screening and follow-up assessments are blinded. The interventionalist and cath lab staff are unblinded.)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Systolic Ambulatory Blood Pressure</measure>
    <time_frame>Baseline to 8 weeks post-treatment</time_frame>
    <description>Change in mean 24-hour ambulatory SBP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Ambulatory Blood Pressure</measure>
    <time_frame>Baseline, and 8 weeks, 6 months, 12 months post treatment</time_frame>
    <description>Change in mean 24-hour, daytime, and nighttime ambulatory SBP and DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Office Blood Pressure</measure>
    <time_frame>Baseline, and 4 weeks, 8 weeks, 3 months, 6 months, 1 year and 2 years post treatment</time_frame>
    <description>Change in mean office SBP and DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responders to target Blood Pressure</measure>
    <time_frame>Baseline, and 4 weeks, 8 weeks, 3 months, 6 months, 1 year and 2 years post treatment</time_frame>
    <description>Percentage of subjects controlled to target blood pressure values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hypertension</condition>
  <condition>Hypertension,Essential</condition>
  <arm_group>
    <arm_group_label>Treatment Arm:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Only renal angiography performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alcohol</intervention_name>
    <description>Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries</description>
    <arm_group_label>Treatment Arm:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham control</intervention_name>
    <description>endovascular, renal angiography</description>
    <arm_group_label>Sham Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has 3 office blood pressure measurements with a mean office systolic blood pressure
             (SBP) of ≥150 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of
             ≥90 mmHg.

          2. Subject is willing to discontinue any current antihypertensive medications during the
             run-in period and the post-treatment period.

          3. Has a mean 24-hour ambulatory SBP of ≥135 mmHg and ≤170 mmHg with ≥70% valid readings

        Exclusion Criteria:

          1. Subject has renal artery anatomy abnormalities.

          2. Subject has an estimated glomerular filtration rate (eGFR) of ≤45 mL/min/1.73 m2,
             based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or
             is on chronic renal replacement therapy.

          3. Subject has documented sleep apnea.

          4. Subject has any of the following conditions: severe cardiac valve stenosis, heart
             failure (New York Heart Association [NYHA] Class III or IV), chronic atrial
             fibrillation, and known primary pulmonary hypertension (&gt;60 mmHg pulmonary artery or
             right ventricular systolic pressure).

          5. Subject is pregnant or lactating at the time of enrollment or planning to become
             pregnant during the trial time period (female subjects only).

          6. Subject is being treated chronically (e.g. daily use) with NSAIDs, immunosuppressive
             medications, or immunosuppressive doses of steroids. Aspirin therapy and nasal
             pulmonary inhalants are allowed.

          7. Subject has a history of myocardial infarction, unstable angina pectoris, or
             stroke/TIA within 6 months prior to the planned procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Mahfoud, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum des Saarlandes Klinik für Innere Medizin III Kardiologie, Angiologie und Internistische Intensivmedizin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atul Pathak, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur Hi-LAB, Toulouse, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Schmalz</last_name>
    <phone>+1 (650) 688-9743</phone>
    <email>dschmalz@ablativesolutions.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debbie Reynolds, PhD</last_name>
    <phone>+1 (650) 688-9743</phone>
    <email>dreynolds@ablativesolutions.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Persu, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atul Pathak, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Mahfoud, Prof.Dr. med</last_name>
    </contact>
    <investigator>
      <last_name>Felix Mahfoud, Prof. Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIHR Barts Cardiovascular Biomedical Research Unit</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Saxena, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manish Saxena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Denervation</keyword>
  <keyword>Neurolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

